Doc #125 — Public Health Surveillance and Disease Prevention

---

RECOMMENDED ACTIONS

Phase 1 — First 48 hours [IMMEDIATE]

1. Confirm operational continuity of the national notifiable disease surveillance system. Contact the Institute of Environmental Science and Research (ESR), all Regional Public Health Units, and the Ministry of Health Communicable Diseases team. Confirm that EpiSurv (NZ’s national notifiable disease database) is operational and that reporting pathways from laboratories, GPs, and hospitals to ESR are intact. [Phase: 1 — IMMEDIATE]

2. Issue guidance to all Medical Officers of Health (MoHs) in each health district: heightened surveillance for waterborne disease, respiratory illness clusters, and any unusual disease presentations. MoHs have statutory authority under the Health Act 1956 and the COVID-19 Public Health Response Act amendments to impose quarantine, isolation, and public health orders — confirm these authorities are understood and ready for use.⁷ [Phase: 1 — IMMEDIATE]

3. Secure all vaccine stocks under the national stockpile framework (Doc #1). Contact the national vaccine distributor and cold-chain managers. Inventory all vaccines held at distributor warehouses, hospital pharmacies, GP practices, community vaccination centres, and pharmacy vaccinators. Integrate with the Doc #116 pharmaceutical inventory. [Phase: 1 — IMMEDIATE]

Phase 1 — First two weeks [URGENT]

4. Complete national vaccine inventory. Aggregate all vaccine stocks by type, quantity, and expiry date. Calculate depletion timelines under current immunisation schedule and under rationed schedules. Publish a vaccine triage framework (Section 4). [Phase: 1 — URGENT]

5. Activate border health measures. Ensure all functioning ports (Auckland, Tauranga, Lyttelton, Wellington, and any others receiving vessels) have public health staff or trained designees capable of health screening arriving passengers and crew. Establish quarantine facilities at or near each port. Pre-event, NZ already had designated quarantine facilities and processes under the Biosecurity Act 1993 and the Health Act 1956 — these must be confirmed operational.⁸ [Phase: 1 — URGENT]

6. Begin nutritional surveillance. Coordinate with the food rationing system (Doc #3) to monitor dietary composition across regions and population groups. Identify populations at highest risk of micronutrient deficiency — particularly communities with limited access to fresh produce, elderly people, children, and pregnant women. [Phase: 1 — URGENT]

7. Issue public health guidance on hygiene and sanitation. Print and distribute guidance on hand hygiene, safe food handling, safe water use, and recognition of symptoms requiring medical attention. This is low-cost, high-value preventive communication. [Phase: 1 — URGENT]

Phase 1 — First three months [HIGH PRIORITY]

8. Establish paper-based surveillance fallback. Design, print (Doc #5, Doc #29), and distribute standardised disease reporting forms to all GPs, hospitals, community health centres, and community health workers. These forms must be simple enough for non-specialist completion and designed for manual aggregation at district level. Digital systems will likely continue functioning for years under the baseline scenario (grid operational, domestic telecom intact), but the paper fallback must exist before it is needed. [Phase: 1]

9. Implement the vaccine triage schedule (Section 4). Shift from the full NZ National Immunisation Schedule to a rationed schedule that prioritises the highest-consequence vaccine-preventable diseases. Communicate the rationale to the public and to health providers. [Phase: 1]

10. Establish community health worker (CHW) training programme. Train volunteers in basic disease recognition, hygiene education, disease reporting, and community-level surveillance. Target: first cohort of 500-1,000 CHWs trained within 6 months. These are not clinicians — they are the eyes and ears of the surveillance system at the community level, analogous to the community health worker programmes that have been effective in low-resource settings globally.⁹ [Phase: 1]

11. Assess and reinforce water and sanitation infrastructure in coordination with Docs #50 and #51. Public health staff should be embedded in the water treatment transition planning to ensure that treatment changes do not inadvertently create disease risk. [Phase: 1]

12. Establish a pest and vermin management framework (Section 8). Issue guidance on waste management, food storage, and rodent control. Identify existing pest control chemical stocks (rodenticides, insecticides) and ration for public health priority use. [Phase: 1]

Phase 1-2 — Months 3-12 [PRIORITY]

13. Begin active TB surveillance. Screen high-risk populations (crowded housing, immunocompromised, previous TB contacts, prison populations, recent arrivals from high-incidence countries) using clinical assessment and, while available, chest X-ray and Mantoux testing. Establish TB treatment protocols using available drug stocks (Doc #116). [Phase: 1-2]

14. Implement STI surveillance and management programme (Section 7). As diagnostic reagents deplete, shift toward syndromic management. Ensure condom distribution and sexual health education continue. [Phase: 1-2]

15. Coordinate housing and public health response. Work with housing authorities (Doc #163) to identify the housing conditions most likely to drive respiratory disease — uninsulated homes, overcrowded households, damp dwellings — and prioritise remediation or rehousing where feasible. [Phase: 1-2]

16. Establish quarantine protocols for all ports receiving vessels. Standardise health screening procedures, quarantine duration, and disease testing requirements for arriving persons and cargo. Coordinate with border management (Doc #145). [Phase: 1-2]

Phase 2-3 — Years 1-7 [STRATEGIC]

17. Transition surveillance to sustainable methods as laboratory consumables deplete. Shift from laboratory-confirmed case definitions to clinical case definitions for most diseases. Maintain laboratory capacity for outbreak investigation and confirmation of novel or high-consequence pathogens. [Phase: 2-3]

18. Scale CHW programme to achieve national coverage — target of at least one trained community health worker per 500-1,000 population. [Phase: 2-3]

19. Develop local diagnostic capacity where possible. Simple laboratory tests (microscopy for malaria and TB, Gram staining for bacterial infections, urine dipstick production) can be maintained or produced domestically. Complex tests (PCR, serology, viral culture) will degrade as reagents deplete. Prioritise maintaining microscopy capability. [Phase: 2-3]

20. Monitor for nutritional deficiency diseases as dietary variety potentially narrows further during peak nuclear winter. Establish clinical surveillance for scurvy, pellagra, and beriberi. Issue treatment protocols (dietary correction, supplementation from local sources where available). [Phase: 2-3]

21. Assess domestic vaccine production feasibility for highest-priority vaccines (tetanus toxoid, measles). This is a long-term project — vaccine manufacturing is complex, requiring sterile production facilities, quality control, and cold-chain distribution. Feasibility is assessed in Section 4.5. [Phase: 2-3]

---

ECONOMIC JUSTIFICATION

The cost of failure

Public health surveillance and disease prevention are among the highest-return investments in the recovery programme. The arithmetic is straightforward:

A single waterborne disease outbreak in a major urban centre — similar in scale to Havelock North but in Auckland (population approximately 1.7 million) — could incapacitate 100,000–400,000 people simultaneously (range depends on pathogen, water system affected, and detection speed), overwhelming the health system, halting recovery work, and potentially killing hundreds to low thousands if antibiotic and rehydration supplies are constrained.¹⁰ Prevention cost: maintaining water treatment and sanitation (Doc #48). Treatment cost if prevention fails: large enough to set back recovery efforts by months, consuming scarce antibiotics and hospital capacity that cannot be replaced.

A measles epidemic in unvaccinated birth cohorts, once population immunity drops below the approximately 93-95% threshold for herd immunity, could infect 50,000-100,000 children and young adults over 1-3 years, with a case fatality rate of 1-3 per 1,000 in well-nourished populations and substantially higher (5-10+ per 1,000) in malnourished populations.¹¹ Prevention cost: maintaining vaccination for as long as stocks last, then managing the transition with outbreak response capability. Treatment cost: hospital beds, antibiotics for secondary bacterial pneumonia, and hundreds of preventable deaths.

A tuberculosis resurgence under crowded, cold, malnourished conditions could produce thousands of active cases per year within a decade, each requiring 6-9 months of multi-drug treatment from finite antibiotic stocks (Doc #116). TB in the pre-antibiotic era had a case fatality rate of approximately 50%.¹²

Person-year investments

Investment	Estimated person-years	Timeline	Return
Surveillance system continuity and paper fallback	5-10	Months 1-6	Early warning of outbreaks — prevents escalation
Community health worker training (first 1,000)	20-40 (including trainers)	Year 1	Extends surveillance reach to every community
Border health screening	10-20 FTE ongoing	Ongoing	Prevents importation of eliminated diseases
Vaccine triage and rationed immunisation	5-10 (planning); existing workforce for delivery	Months 1-6 (planning)	Extends the protective value of finite vaccine stocks by years
Pest and vermin management	10-20 FTE ongoing	Ongoing	Prevents rodent-borne disease and food contamination
Nutritional surveillance	5-10 FTE ongoing	Ongoing	Early detection of deficiency diseases

Total ongoing public health workforce requirement: Approximately 100-200 FTE across all public health functions, drawn largely from NZ’s existing public health workforce of approximately 2,000-3,000 professionals (Medical Officers of Health, public health nurses, health protection officers, epidemiologists, environmental health officers).¹³ The community health worker programme adds lay workers who can be trained in months, not years.

Comparison with alternatives:

• Maintain the current system unchanged: Not possible — consumable inputs (vaccines, diagnostic reagents, laboratory supplies) deplete. The system must adapt.
• Abandon formal surveillance: Outbreaks are detected late or not at all. Response is reactive rather than preventive. Disease burden escalates. The recovery effort is undermined by a sick workforce. This is the worst option.
• Recommended approach: Adapt the existing system to work with declining imported inputs, extend surveillance through community health workers, maintain outbreak response capability, and invest in the highest-return preventive interventions (water, sanitation, vaccination while stocks last, hygiene education). This is the approach that maximises population health per unit of invested effort.

---

1. NZ’S PUBLIC HEALTH INFRASTRUCTURE

1.1 The institutional framework

NZ’s communicable disease surveillance and response system operates through several interlocking institutions:¹⁴

The Ministry of Health / Manatu Hauora sets national policy for communicable disease control, administers the Immunisation Schedule, and coordinates the national response to outbreaks. The Communicable Diseases team within the Ministry provides epidemiological analysis and policy guidance.

The Institute of Environmental Science and Research (ESR) is NZ’s Crown Research Institute responsible for infectious disease surveillance and reference laboratory services. ESR operates EpiSurv, the national notifiable disease database, and provides the scientific backbone of disease surveillance — confirmatory testing, outbreak investigation support, molecular typing, and antimicrobial resistance monitoring.¹⁵ ESR also operates the national enteric reference laboratory (identifying and typing foodborne and waterborne pathogens) and the WHO National Influenza Centre for NZ.

Regional Public Health Units (RPHUs) — currently operating within Te Whatu Ora / Health New Zealand’s regional structure — are the operational arm of public health at the district level. Each RPHU is led by a Medical Officer of Health (MoH) with statutory powers under the Health Act 1956, including the power to order quarantine, isolation, medical examination, and closure of premises. RPHUs receive notifiable disease reports, investigate cases and outbreaks, manage contacts, and implement control measures.¹⁶

General practitioners, hospitals, and laboratories are the front line of disease detection. Under the Health Act 1956, specified diseases are legally notifiable — medical practitioners and laboratories must report cases to the local Medical Officer of Health. NZ’s notifiable disease schedule includes approximately 50 conditions, ranging from measles and meningococcal disease to campylobacteriosis and tuberculosis.¹⁷

1.2 How surveillance currently works

The surveillance chain operates as follows:

1. A patient presents to a GP or hospital with symptoms
2. The clinician suspects a notifiable condition and either clinically notifies the MoH directly or orders a laboratory test
3. The laboratory confirms the diagnosis and notifies both the clinician and the MoH (laboratory notification is mandatory for confirmed cases)
4. The RPHU receives the notification, enters it into EpiSurv, investigates the case (contact tracing, source identification), and implements control measures
5. ESR aggregates national data from EpiSurv, analyses trends, and publishes surveillance reports

Strengths of this system: It is well-established, legally mandated, electronically networked, and staffed by trained professionals. NZ’s small size means that national-level analysis is feasible — ESR can detect emerging patterns across the whole country within days.

Vulnerabilities under isolation:

• Laboratory dependence. Most confirmatory testing requires imported reagents — culture media, serological test kits, PCR reagents, antimicrobial susceptibility testing supplies. As these deplete, laboratory-confirmed surveillance degrades toward clinical (symptom-based) surveillance, which is less specific and generates more false positives.
• Digital infrastructure dependence. EpiSurv runs on digital infrastructure (servers, internet connectivity, workstations). Under the baseline scenario (grid and domestic telecom functional), this continues for years. But if digital systems degrade, surveillance must have a paper-based fallback.
• Workforce concentration. Public health professionals are concentrated in urban centres. Rural communities — particularly remote Maori and farming communities — are underserved for public health surveillance.

1.3 Pre-event disease burden

NZ’s baseline disease burden is relevant because it determines which existing problems are likely to worsen under crisis conditions:¹⁸¹⁹

Disease category	Pre-event NZ burden	Post-event trajectory
Campylobacteriosis	~6,000-7,000 notified cases/year — NZ’s most commonly notified disease	Likely increases if water treatment lapses or food hygiene declines
Salmonellosis	~1,000-1,200 cases/year	Increases with food handling changes
Giardiasis	~1,000-1,500 cases/year	Increases if water treatment degrades
Cryptosporidiosis	~700-1,000 cases/year	Increases with water and animal contact
Influenza	Seasonal, variable — thousands of cases/year, 400-500+ deaths in severe years	Worsens with cold housing, crowding, vitamin deficiency. Vaccine stocks finite
Tuberculosis	~300-350 cases/year (~6-7 per 100,000)	Risk of increase with crowding, malnutrition, cold housing. Serious long-term concern
Rheumatic fever	~100-170 first episodes/year — disproportionately Maori and Pacific children	Worsens with overcrowding, damp housing, delayed treatment of strep throat
Measles	Sporadic outbreaks (major outbreak 2019, ~2,194 cases)	Re-emergence likely once vaccine-derived immunity wanes
Pertussis (whooping cough)	Cyclic epidemics every 3-5 years, ~1,000-2,000 cases in epidemic years	Worsens as vaccine coverage declines
Meningococcal disease	~50-100 cases/year	Increases with crowding
Hepatitis B	~50-80 acute cases/year; chronic carriers ~100,000	Chronic carriers continue; vaccine loss affects future protection
STIs (chlamydia, gonorrhoea, syphilis)	Chlamydia ~20,000+; gonorrhoea ~4,000-6,000/year	Increases as condom supply depletes and diagnostic/treatment capacity declines

1.4 NZ’s island advantage

This deserves explicit statement because it is the single most important structural factor in NZ’s public health position: NZ is an island nation with no land borders. Every person and every pathogen that enters NZ arrives by sea or air. Under isolation, air travel ceases. Maritime arrivals are controllable. NZ can, in principle, prevent the importation of any disease that it does not already harbour, provided border health measures are maintained.

This advantage was demonstrated during COVID-19, when NZ’s border controls — however politically contentious — effectively prevented community transmission for extended periods.²⁰ The principle applies to any future disease threat: if NZ maintains functional health screening and quarantine at ports, it can keep out cholera, drug-resistant TB, novel influenza strains, and other threats that may circulate in less fortunate countries.

The caveat: this advantage is only as strong as the border health system. If ports operate without health screening — because of workforce shortages, political pressure to admit arrivals quickly, or simple neglect — NZ loses its most valuable public health asset.

---

2. WATERBORNE DISEASE AND SANITATION

2.1 The primary public health intervention

If this document could make only one recommendation, it would be this: maintain safe water and sanitation. The history of public health is unambiguous — clean water and effective sanitation have prevented more disease and saved more lives than any other intervention, including vaccines and antibiotics.²¹ Under isolation, where pharmaceutical resources are finite and declining, prevention through water and sanitation becomes even more important relative to treatment.

Doc #48 (Water Treatment Without Imports) and Doc #49 (Wastewater Management) address the infrastructure side. This section addresses the disease surveillance and public health response side.

2.2 Risks and monitoring

The specific risks of water treatment degradation are:

• Campylobacter: NZ’s most common notifiable enteric disease. Transmitted through contaminated water, undercooked poultry, and unpasteurised milk. NZ already has one of the highest campylobacteriosis rates in the developed world, partly due to agricultural water contamination.²²
• Cryptosporidium and Giardia: Protozoan parasites resistant to standard chlorination. Effective removal requires filtration (slow sand filtration is effective) or UV treatment. If treatment lapses to chlorination alone without adequate filtration, these organisms pose increased risk.²³
• E. coli O157 and other enteric pathogens: Risk increases with any degradation in water treatment or food hygiene.
• Norovirus and rotavirus: Transmitted faecal-orally; water and food vehicles. Norovirus is resistant to low-level chlorination.

Monitoring protocol:

1. Sentinel surveillance at water treatment plants. Monitor raw and treated water quality at all municipal plants. Under standard practice, this uses E. coli and total coliform testing — both require laboratory culture media that will eventually deplete. Fallback: hydrogen sulfide (H₂S) paper strip tests for faecal contamination are simple, cheap, and can be produced locally (filter paper impregnated with iron citrate and sodium thiosulfate).²⁴ The performance gap: H₂S tests detect faecal contamination with moderate sensitivity (approximately 70–85%) and specificity (approximately 70–80%) compared with standard E. coli culture methods; they produce both false positives and false negatives and cannot quantify contamination levels. They are adequate for field screening — a positive result triggers further investigation — but are not a replacement for quantitative water quality testing.
2. Clinical surveillance for diarrhoeal disease clusters. Any increase in diarrhoeal illness presentations at GPs, hospitals, or through CHW reports should trigger immediate investigation of the water supply serving that community.
3. Sanitation monitoring. Ensure wastewater systems continue functioning. Monitor for overflows, especially after heavy rainfall. Track sewage disposal in communities without reticulated wastewater systems.

2.3 Household-level water safety

Not all NZ households receive treated municipal water. Approximately 15-20% of the population — predominantly rural — relies on private water supplies (rainwater tanks, private bores, untreated streams).²⁵ These populations are already at higher risk of waterborne disease under normal conditions and will be at increased risk as veterinary pharmaceutical use for livestock changes, as human waste management practices potentially degrade in rural areas, and as the oversight capacity of territorial authorities diminishes.

Public health guidance for private supplies:

• Boil water before drinking if treatment status is uncertain (rolling boil for 1 minute)
• Maintain rainwater tank hygiene: first-flush diverters, covered tanks, regular cleaning
• Keep livestock out of waterways upstream of water intake points
• If using bore water, monitor for contamination indicators (colour change, odour, illness in users)
• For gastrointestinal complaints from suspected waterborne exposure, koromiko (Veronica salicifolia) has documented traditional use for diarrhoeal illness and extends the clinical toolkit when pharmaceutical stocks are constrained²⁶

This guidance should be printed, distributed through community health workers, and repeated regularly. Traditional tapu protocols — which maintained strict separation between water sources, food preparation, and waste disposal — served public health functions analogous to modern hygiene practice.²⁷ These cultural frameworks can reinforce hygiene messaging in communities, particularly where they align with existing cultural values rather than being imposed as external rules.

---

3. NUTRITIONAL DEFICIENCY DISEASES

3.1 Why this matters now

NZ’s pre-event diet is varied and nutritionally adequate for most of the population (with notable exceptions in low-income households and some Maori and Pacific communities).²⁸ Under isolation, dietary variety narrows. The specific risk depends on how the food system adapts:

• If the diet becomes heavily dependent on a small number of staples — potatoes, meat, dairy — micronutrient deficiencies become likely.
• If the rationing system (Doc #3) successfully delivers a varied diet including vegetables, fruit, organ meats, dairy, and whole grains, deficiency diseases are preventable.
• The period of greatest risk is Phase 2 (years 1-3), when nuclear winter most severely constrains production and pre-event food stocks have been partially consumed.

3.2 Specific deficiency risks

Scurvy (vitamin C deficiency). Onset after approximately 1-3 months of dietary vitamin C depletion.²⁹ Symptoms: fatigue, gum disease, poor wound healing, joint pain. Fatal if untreated. NZ food sources of vitamin C that can be maintained under nuclear winter: potatoes (modest vitamin C, but eaten in quantity), cabbage, puha (Sonchus oleraceus — a traditional Maori green vegetable that grows as a weed and tolerates cold conditions), watercress (grows in NZ waterways year-round), rosehips, and kiwifruit (production will decline but some fruit will persist in milder regions). Blackcurrants are an excellent source and are commercially grown in NZ, particularly in Canterbury.³⁰ The risk is highest in populations eating a restricted diet without fresh vegetables — elderly people receiving institutional meals, prisoners, isolated rural communities, and any population subsisting primarily on stored grain and preserved meat.

Pellagra (niacin/vitamin B3 deficiency). Risk arises if the diet becomes heavily maize-dependent, which is unlikely in NZ given the predominance of wheat and potatoes, but possible in communities relying on stored maize without proper preparation (nixtamalization releases bound niacin). Meat, fish, and dairy — all available in NZ — are good niacin sources. Risk is low unless dietary diversity collapses severely.³¹

Beriberi (thiamine/vitamin B1 deficiency). Risk arises with diets dependent on white rice or refined grains. NZ does not produce significant quantities of rice but does import it, and pre-event stocks may last 1-2 years. The risk is primarily in Pacific and Asian communities whose traditional diets include white rice. Whole grains, meat, and legumes provide adequate thiamine. Risk is low-moderate.³²

Iron-deficiency anaemia. Already the most common nutritional deficiency in NZ, particularly affecting women of reproductive age, Maori, and Pacific peoples.³³ Under crisis conditions, with reduced red meat access during peak rationing, the prevalence will increase. Consequences: fatigue, reduced work capacity, impaired cognitive function, increased vulnerability to infection, and increased risk of complications in pregnancy (Doc #123). NZ food sources: red meat (available from destocking and ongoing pastoral farming), liver (excellent iron source — should be specifically included in ration guidance), puha, watercress, and shellfish.

Vitamin D deficiency. Nuclear winter reduces sunlight, which is the primary source of vitamin D for most people. NZ already has significant vitamin D deficiency, particularly in darker-skinned populations and during winter months.³⁴ Reduced sunlight during nuclear winter will worsen this. Dietary sources in NZ: oily fish (if fisheries are maintained — Doc #78), egg yolks, liver. Cod liver oil, if fisheries produce it, is an excellent combined source of vitamins A and D. Vitamin D supplementation stocks will deplete with the broader pharmaceutical supply (Doc #116). This is a genuine gap.

Vitamin A deficiency. NZ dairy production provides butter and cheese (good vitamin A sources). Liver is excellent. Orange and green vegetables (pumpkin, kumara, silverbeet, spinach) provide beta-carotene. Risk is low unless dairy and vegetable access both collapse.³⁵

3.3 Surveillance and response

Surveillance: Community health workers trained to recognise the clinical signs of nutritional deficiency — bleeding gums and loose teeth (scurvy), skin rash in sun-exposed areas (pellagra), oedema and neurological symptoms (beriberi), pallor and fatigue (anaemia). Clinical suspicion triggers dietary assessment and intervention.

Response: Nutritional deficiency diseases are treated by correcting the diet, not by pharmaceuticals (though vitamin supplements are used for rapid correction when available). The primary intervention is to ensure the food rationing system (Doc #3) delivers adequate micronutrient variety. Specific actions:

• Include fresh vegetables, particularly dark leafy greens, in rations wherever possible
• Promote organ meat consumption (liver is the single most nutrient-dense food readily available in NZ)
• Encourage home and community gardening focused on vitamin-rich crops: silverbeet, cabbage, puha, parsley, broccoli, pikopiko (fern fronds), and watercress — all provide micronutrients that may be absent from a narrowed rationed diet³⁶
• Incorporate kaimoana (seafood) including kina, paua, and seaweed as micronutrient sources where coastal access permits — these provide iron, iodine, and omega-3 fatty acids not available from a purely pastoral diet
• Support marae-based food systems and community gardens drawing on established horticultural knowledge, which can supplement rationed diets and serve as distribution points for nutritional guidance
• Maintain dairy distribution — butter, cheese, and milk provide vitamins A and D and multiple B vitamins
• Distribute dietary guidance through community health workers, schools, and marae
• Where pharmaceutical supplies are constrained, kawakawa (Piper excelsum) for skin infections and wound care, and manuka honey for wound management (well-established antibacterial properties), extend the clinical toolkit for managing common conditions³⁷

---

4. VACCINE STOCKS AND IMMUNISATION STRATEGY

4.1 NZ’s vaccine dependency

NZ imports all of its vaccines. There is no domestic vaccine manufacturing capability.³⁸ The national immunisation programme — which delivers approximately 1.5–2.5 million doses per year across all age groups for the National Immunisation Schedule (estimate based on NZ’s birth cohort of approximately 58,000–62,000 per year, multi-dose childhood schedules, and adult booster and influenza programmes)³⁹ — depends entirely on imported products distributed through the national cold chain.

NZ National Immunisation Schedule (pre-event) — key vaccines:⁴⁰

Vaccine	Target diseases	Schedule	Population
DTaP-IPV-HepB/Hib (Infanrix-hexa)	Diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae b	6 weeks, 3 months, 5 months	Infants
MMR (Priorix)	Measles, mumps, rubella	12 months, 15 months	Infants/toddlers
PCV13 (Prevenar 13)	Pneumococcal disease	6 weeks, 5 months, 12 months	Infants
Tdap (Boostrix)	Diphtheria, tetanus, pertussis booster	11 years; pregnancy	Adolescents, pregnant women
HPV (Gardasil 9)	Human papillomavirus	12 years	Adolescents
Influenza	Seasonal influenza	Annual	Over-65s, high-risk, pregnant women
Td (ADT Booster)	Tetanus, diphtheria	As needed (wound management)	All ages

4.2 Depletion timeline

Estimate: NZ’s vaccine cold chain holds approximately 3-12 months of supply for most vaccines, depending on the vaccine and the time of year (influenza vaccine is seasonal; childhood vaccines are stocked more evenly).⁴¹ Vaccine shelf life under proper cold-chain storage is typically 2-3 years from manufacture. Assuming that stocks at the time of the event represent a mix of recently manufactured and approaching-expiry products, the effective supply window for most vaccines is approximately 2-4 years if rationed, possibly shorter if cold chain is compromised at any point.

Cold-chain vulnerability: All vaccines require refrigeration (2-8 degrees C), and some (e.g., varicella, some influenza formulations) require freezer storage (-15 to -25 degrees C). Under the baseline scenario (grid operational), cold chain continues. If power is interrupted — even briefly — at vaccine storage facilities, stocks may be destroyed. Backup power at national and regional vaccine storage centres is a high priority (same infrastructure protecting insulin stocks — Doc #116).⁴²

Vaccine-specific depletion estimates:

Vaccine	Estimated supply duration (rationed)	Consequence of depletion
MMR	2-4 years	Measles re-emergence once unvaccinated cohort grows large enough
DTaP-IPV-HepB/Hib	2-4 years	Tetanus, diphtheria, pertussis risk increases
Td/Tdap boosters	2-4 years	Tetanus risk for wound management; pertussis boosters lost
PCV13	2-3 years	Pneumococcal disease increases in young children
Influenza	1-2 years (seasonal stock)	Annual flu outbreaks without vaccine mitigation
HPV	2-3 years	Long-term cervical cancer prevention lost
BCG (currently targeted)	Limited stock	TB prevention in high-risk groups lost

4.3 Vaccine triage framework

When vaccine supply is finite, every dose must be allocated for maximum population-level benefit. The triage framework prioritises vaccines based on:

1. Severity of the disease prevented — case fatality rate, disability rate, outbreak potential
2. Effectiveness of the vaccine — how many cases prevented per dose
3. Availability of alternative prevention — can the disease be controlled by non-vaccine means?
4. Population at risk — how many people are vulnerable if vaccination stops?

Priority 1 — Highest value per dose:

• Measles (MMR): Measles is the most contagious vaccine-preventable disease (R₀ approximately 12-18). Herd immunity requires approximately 93-95% coverage. Once coverage drops below this threshold, outbreaks are inevitable. Measles case fatality rate in well-nourished populations is approximately 1-3 per 1,000; in malnourished populations it can exceed 5-10 per 1,000.⁴³ Every dose of MMR given to a previously unvaccinated child prevents more disease than almost any other single medical intervention. Recommendation: Prioritise MMR for all infants and unvaccinated children. This is the last childhood vaccine to be discontinued.

• Tetanus (Td): Tetanus is not transmitted person-to-person, so herd immunity is irrelevant — individual protection matters. Under recovery conditions, the agricultural and manual labour workforce faces dramatically increased tetanus exposure: soil contact, wounds from tools and equipment, animal handling. Tetanus case fatality rate without intensive care is approximately 20-50%; with the limited intensive care available post-event, it may be higher.⁴⁴ Recommendation: Prioritise tetanus boosters for agricultural workers, construction workers, and anyone regularly exposed to soil and wound risk. Maintain tetanus toxoid for wound management at all health facilities.

Priority 2 — High value:

• Pertussis (DTaP for infants, Tdap for pregnant women): Pertussis is most dangerous in young infants, with a case fatality rate of approximately 1-2% in infants under 6 months.⁴⁵ Maternal vaccination in pregnancy transfers protective antibodies to the newborn. Recommendation: Maintain pertussis vaccination for infants and pregnant women as long as stocks allow.

• Pneumococcal (PCV13): Pneumococcal disease is a significant cause of pneumonia, meningitis, and sepsis in young children. Recommendation: Continue PCV13 for infants while stocks last; discontinue before MMR.

Priority 3 — Important but lower priority under rationing:

• Influenza: Prevents significant morbidity and some mortality, particularly in elderly and high-risk groups. However, influenza is seasonal, and vaccine must be reformulated annually for circulating strains — without ongoing international strain surveillance, future flu vaccine batches (if they existed) would be of uncertain relevance. Recommendation: Use existing influenza vaccine stocks for the first 1-2 seasons, prioritising healthcare workers and elderly. Accept that influenza vaccination will cease within 1-2 years.

• Hepatitis B: The infant hepatitis B series provides long-term protection. Most adults at risk are already vaccinated or have natural immunity. Recommendation: Continue infant hepatitis B vaccination while combined vaccine (Infanrix-hexa) stocks last; do not maintain as a standalone priority after combined stocks are exhausted.

Priority 4 — Defer or discontinue:

• HPV: Prevents cervical cancer over decades. The benefit timeline is too long relative to vaccine scarcity — the immediate public health return per dose is low compared with measles or tetanus. Recommendation: Discontinue when supply constraints require prioritisation. Cervical screening (if Pap smear capability can be maintained) provides an alternative prevention pathway.

• Varicella (chickenpox): Generally mild in childhood. Case fatality is very low in healthy children. Recommendation: Discontinue early.

4.4 Managing the post-vaccine transition

When vaccines are exhausted, the diseases they prevented will return. The timeline depends on the disease:

Measles: NZ’s current population immunity is high (approximately 92-95% of children vaccinated; most adults immune from vaccination or prior infection). Unvaccinated birth cohorts accumulate at approximately 55,000–62,000 per year (NZ’s recent annual birth cohort, which may decline under crisis conditions).⁴⁶ If vaccination ceases after year 3, by year 8 approximately 200,000–310,000 children aged 0–5 would be unvaccinated (range accounts for uncertainty in both birth rates under crisis conditions and the timing of vaccine exhaustion). A measles introduction at that point — from a refugee vessel, a returning trade crew, or a remaining chain of transmission — could infect a large proportion of this cohort. NZ experienced exactly this pattern in 2019, when a measles outbreak (approximately 2,194 confirmed cases) spread primarily through under-vaccinated communities.⁴⁷

Response to measles re-emergence (without vaccine):

• Rapid case detection and isolation (surveillance system must be functioning)
• Contact tracing and quarantine of exposed unvaccinated individuals
• Ring vaccination using any remaining MMR stocks (reserve a national emergency stockpile of MMR for outbreak response even after routine vaccination ceases)
• Supportive care: vitamin A supplementation reduces measles severity and mortality (evidence from WHO recommendations for developing countries)⁴⁸ — NZ can supply vitamin A through liver and dairy even without supplement capsules
• Accept that measles will become endemic again, as it was before vaccination. Focus on reducing mortality through nutritional support and clinical care, rather than on preventing all transmission.

Tetanus: Unlike measles, tetanus does not spread person-to-person, so there is no epidemic risk. But individual cases will occur in any unprotected person who sustains a contaminated wound. Without vaccine boosters, the proportion of the working-age population with protective tetanus antibody levels will decline over approximately 10-20 years. Wound management protocols must include thorough wound cleaning and debridement — the pre-vaccine tetanus prevention measures — and tetanus immune globulin (TIG) from stocks while available.

Pertussis: Will return in epidemic cycles (historically every 3-5 years). Infant mortality from pertussis is the primary concern. Without vaccine, prevention relies on isolating coughing contacts from young infants and maintaining awareness of pertussis as a diagnosis. Erythromycin (antibiotic) reduces transmission if given early — rationed use from Doc #116 stocks.

4.5 Domestic vaccine production: honest assessment

Can NZ produce vaccines domestically?

Tetanus toxoid: Tetanus toxoid is produced by growing Clostridium tetani in anaerobic culture, harvesting the exotoxin, and inactivating it with formaldehyde. The dependency chain: anaerobic culture requires oxygen-free fermentation vessels (custom fabrication from stainless steel or glass), culture media (peptone digest — producible from animal tissue, plus glucose and mineral salts), sterile technique throughout (autoclave sterilisation — NZ hospitals have autoclaves), formaldehyde for toxoid inactivation (producible by catalytic oxidation of methanol, which is producible from wood distillation — Doc #119), sterile filtration equipment, and — critically — quality control testing to verify toxoid potency and confirm that active toxin has been fully inactivated (an under-inactivated batch would cause tetanus, not prevent it). Quality control requires animal testing capability (mouse or guinea pig potency assays) or, eventually, in-vitro alternatives. Feasibility: [C] — the fermentation is achievable with 1920s-era technology, but building reliable quality assurance is the binding constraint. Timeline: 5–15 years with dedicated effort. This should be a priority for the medical production programme (Doc #119) because tetanus is the highest-consequence vaccine-preventable disease for the working population.

Measles vaccine: Measles vaccine is a live attenuated virus produced in cell culture (typically chick embryo fibroblasts). This requires virological laboratory capability, cell culture expertise, and stringent quality control — live viral vaccines that are insufficiently attenuated cause disease rather than preventing it. Feasibility: [C-D] — substantially more complex than tetanus toxoid production. NZ has virological research capacity at universities and ESR, but vaccine manufacturing is qualitatively different from research virology. Timeline: 10-25+ years. This is a long-term aspiration, not a near-term solution.

BCG (tuberculosis) vaccine: Produced from an attenuated strain of Mycobacterium bovis. Requires mycobacterial culture capability, which is more complex than standard bacteriology. Feasibility: [C] — similar difficulty to tetanus toxoid but with additional biosafety requirements.

Honest summary: Domestic vaccine production is possible but requires years to decades of capability building. In the interim, NZ relies on existing stocks (rationed as described above), non-vaccine disease prevention measures, and — eventually — trade with partners who may develop production capability sooner.

---

5. TUBERCULOSIS: THE LONG-TERM THREAT [Phase 2–5]

5.1 Why TB is different

Most of the disease risks in this document are immediate or short-term. Tuberculosis is the exception — it is a slow-burning threat that may not manifest for years but could become NZ’s most serious infectious disease problem in the medium to long term.

TB thrives under conditions of:⁴⁹

• Overcrowding — respiratory droplet transmission is more efficient in close quarters
• Malnutrition — weakened immune response allows latent TB to reactivate
• Cold, damp housing — indoor congregation in poorly ventilated spaces
• Immune suppression — HIV (low prevalence in NZ, approximately 1,200-1,500 diagnosed cases)⁵⁰, malnutrition, stress
• Delayed diagnosis and treatment — untreated active TB cases each infect an estimated 5–15 others per year, depending on living conditions, ventilation, and contact patterns⁵¹

Every one of these risk factors worsens under nuclear winter and isolation. NZ’s current TB incidence of approximately 6-7 per 100,000 per year (approximately 300-350 cases) is low, but the country has a significant pool of latent TB infection — particularly among foreign-born residents from high-incidence countries (India, Philippines, China, Pacific Islands).⁵² Approximately 10% of people with latent TB develop active disease during their lifetime; this proportion increases substantially with malnutrition and immune suppression.

5.2 Modelling the risk

Assumption: NZ has approximately 50,000–100,000 residents with latent TB infection (estimate based on immigration patterns and country-of-origin TB prevalence, with significant uncertainty).⁵³ Under crisis conditions — increased crowding, reduced nutrition, stress, cold housing — reactivation rates could increase substantially from the baseline approximately 5–10% lifetime risk. The magnitude of increase is uncertain: historical precedents (wartime Europe, post-Soviet economic collapse) suggest reactivation rates can increase 2–4 fold under sustained deprivation. If 3,000–15,000 additional TB reactivations occur over 5–10 years (range reflects uncertainty in both the latent pool size and the reactivation multiplier), and each active case infects an estimated 5–15 others before detection and treatment, secondary transmission could produce hundreds to thousands of additional cases per year by Phase 3–4.

This is a worst-case projection, not a prediction. The actual trajectory depends on: - How effectively housing and nutrition interventions prevent the conditions that drive TB - How quickly the surveillance system detects new cases - Whether TB drug stocks (isoniazid, rifampicin, pyrazinamide, ethambutol) last long enough to treat cases and prevent transmission - Whether BCG vaccination (targeted programme in NZ for high-risk children) can be maintained

5.3 TB drug supply

Standard TB treatment requires 6-9 months of multi-drug therapy. NZ’s TB drug stocks will last for current caseloads for several years (TB drugs are used in relatively small quantities compared with common antibiotics), but a significant increase in caseload would accelerate depletion. Isoniazid is a relatively simple molecule that is a candidate for domestic production (Doc #119).⁵⁴

Rationing consideration: TB treatment is high-value per dose because untreated active TB is both fatal (approximately 50% case fatality over 2 years without treatment) and highly transmissible. Completing full treatment courses — rather than partial treatment, which drives drug resistance — must be prioritised. Directly Observed Therapy (DOT), where a health worker watches the patient take each dose, is the standard approach and should be maintained.⁵⁵

5.4 Prevention

• Housing and ventilation: The most important TB prevention measure after treatment of active cases. Doc #163 (Housing Insulation) addresses this. Public health input into housing policy should specifically address TB risk: avoid overcrowding, improve ventilation, insulate against cold.
• Nutrition: Adequate nutrition reduces TB reactivation. This links directly to Doc #3 (Food Rationing) — food policy is TB policy.
• Case finding and contact tracing: Active surveillance for TB symptoms (chronic cough >2 weeks, weight loss, night sweats, fever). Community health workers trained to recognise these symptoms and refer for evaluation. Chest X-ray screening while X-ray equipment is functional.
• BCG vaccination: If BCG stocks are available, continue targeted vaccination for high-risk infants (children of parents from high-incidence countries, children in high-risk communities). BCG is approximately 70-80% effective against severe childhood TB (TB meningitis, miliary TB) but much less effective against pulmonary TB in adults.⁵⁶

---

6. RESPIRATORY DISEASE AND HOUSING [Phase 1–4]

6.1 NZ’s pre-existing problem

NZ has some of the coldest, dampest, most poorly insulated housing stock in the developed world. This is not a crisis-related claim — it is a well-documented pre-existing public health failure. The WHO recommends minimum indoor temperatures of 18 degrees C; many NZ homes routinely fall below this in winter, particularly older houses and rental properties.⁵⁷ The consequence: NZ has high rates of respiratory disease, particularly in Maori and Pacific communities, and excess winter mortality that is large by international standards.

Rheumatic fever is the signature disease of NZ’s housing failure. NZ has rheumatic fever rates 10-20 times higher than comparable developed countries, driven by overcrowded housing conditions that facilitate Group A Streptococcus transmission, particularly among Maori and Pacific children in South Auckland and other high-deprivation areas.⁵⁸ Rheumatic fever leads to rheumatic heart disease — permanent heart valve damage requiring lifelong penicillin prophylaxis.

6.2 Post-event worsening

Under nuclear winter conditions: - Outdoor temperatures drop an estimated 3–8 degrees C (range depends on nuclear winter severity models and NZ’s maritime climate buffering; see Doc #76 for temperature modelling assumptions).⁵⁹ Indoor temperatures in uninsulated homes drop similarly unless heating increases. - Fuel for heating may be constrained. Wood is the most sustainable heating fuel in NZ (Doc #102 for charcoal production, Doc #56 for wood gasification), but demand will exceed easy supply in urban areas. Electricity for heating continues under the baseline scenario (grid functional), but load management may limit household heating allocation. - Overcrowding increases if households consolidate for warmth, if refugee arrivals increase population density, or if housing damage reduces stock. - Nutrition declines during peak nuclear winter, reducing immune function.

The combined effect: more respiratory infections, more severe respiratory infections, more rheumatic fever, more pneumonia, and potentially more TB.

6.3 Public health response

This is a case where public health and housing policy must be coordinated. The public health response cannot fix housing — but it can:

• Advocate for housing insulation and heating as public health priorities (Doc #162)
• Monitor respiratory disease rates as an indicator of housing conditions. If respiratory illness increases sharply in a district, the housing conditions in that district need urgent attention.
• Distribute guidance on indoor air quality: ventilate homes even when cold (brief, regular window-opening reduces pathogen concentration); dry wet clothing outside, not inside; manage indoor humidity to reduce mould
• Maintain antibiotic access for streptococcal infections (to prevent rheumatic fever) and pneumonia. Penicillin for strep throat is one of the highest-value antibiotic uses under rationing (Doc #116).
• Support school-based health programmes in high-deprivation areas: sore throat testing and treatment for rheumatic fever prevention (NZ already has such programmes, primarily in South Auckland and other high-risk areas)⁶⁰

---

7. STI MANAGEMENT [Phase 1–5]

7.1 The challenge

Sexually transmitted infections will become harder to manage as three inputs deplete simultaneously:

1. Diagnostic reagents. STI diagnosis currently relies on laboratory testing — NAAT (nucleic acid amplification testing) for chlamydia and gonorrhoea, serology for syphilis and HIV. These tests require imported reagents. When reagents deplete, STI diagnosis shifts to syndromic management (treating based on symptoms rather than confirmed diagnosis). The performance gap is significant: NAAT testing for chlamydia and gonorrhoea has sensitivity above 90%; syndromic management has sensitivity of approximately 40–60% for urethral discharge and lower for cervicitis, meaning roughly half of infections are missed. It also leads to over-treatment of uninfected patients, wasting scarce antibiotics.⁶¹

2. Antibiotics. Chlamydia treatment (azithromycin or doxycycline), gonorrhoea treatment (ceftriaxone — increasingly the only effective option due to antimicrobial resistance), and syphilis treatment (penicillin) all draw from finite stocks (Doc #116). Antibiotic resistance in gonorrhoea is an existing pre-event concern that worsens if treatment becomes inconsistent.

3. Condoms. NZ imports all condoms. Latex condom shelf life is approximately 5 years. Stocks will last several years but eventually deplete. Domestic production of animal-membrane condoms (from sheep caecum — NZ has the raw material) is technically feasible and historically proven, but the performance gap is real: animal-membrane condoms are effective for pregnancy prevention but have pores (approximately 1.5 micrometres) large enough to allow passage of viral particles including HIV, hepatitis B, and HPV. They reduce but do not prevent viral STI transmission, and should be presented as a partial measure for STI prevention — substantially better than nothing, but not equivalent to latex.⁶²

7.2 Priorities

• Syphilis is the highest-priority STI because untreated syphilis causes severe morbidity and mortality (cardiovascular syphilis, neurosyphilis) and congenital syphilis in pregnancy causes stillbirth, neonatal death, and severe disability (hydrops fetalis, bone deformities, neurological damage). Syphilis is treatable with penicillin, which is among the earliest candidates for domestic production (Doc #119). Syphilis diagnosis can be maintained longer than other STI diagnostics because the rapid plasma reagin (RPR) test is relatively simple and its reagents may be producible domestically.⁶³

• Gonorrhoea is increasingly resistant to antibiotics, and the trend toward pan-resistance is a global pre-event concern. Under isolation, if NZ’s circulating gonorrhoea strains are susceptible to available antibiotics, treatment remains feasible. If resistance develops (which is likely over time without antimicrobial stewardship), treatment options narrow. Prevention (condoms, partner reduction, treatment of symptomatic cases to reduce transmission) becomes more important.

• HIV prevalence in NZ is low (approximately 1,200-1,500 diagnosed, with an estimated total including undiagnosed of perhaps 2,000-3,000).⁶⁴ Antiretroviral therapy (ART) stocks will deplete within 2-5 years (Doc #116). For people living with HIV, ART depletion is analogous to insulin depletion for Type 1 diabetes — eventually fatal without treatment. Prevention of new infections through condom use and behaviour change becomes paramount once treatment capacity declines.

• Chlamydia is the most common STI in NZ but causes less acute morbidity than syphilis or gonorrhoea. Under syndromic management (treating symptomatic urethritis and cervicitis), many chlamydia cases will be treated coincidentally. Untreated chlamydia can cause pelvic inflammatory disease and infertility in women — a significant long-term concern but not an acute survival threat.

7.3 Surveillance

Shift STI surveillance from laboratory-confirmed to syndromic reporting as diagnostic reagents deplete. Community health workers and primary care providers trained to recognise syndromic presentations (urethral discharge, genital ulcers, vaginal discharge) and report through the surveillance system. Antenatal syphilis screening — critical for preventing congenital syphilis — should be maintained using RPR testing for as long as reagents allow, and antenatal clinical screening (history, symptoms, partner history) thereafter.

---

8. PEST AND VERMIN MANAGEMENT [Phase 1–5]

8.1 Why this is a public health issue

Rats, mice, and flies are disease vectors and food contaminants. Under crisis conditions, waste management may degrade, food storage practices may change (more community and household food preservation, less sealed commercial packaging), and urbanised populations may lack experience managing vermin. The result: increased rodent and insect populations in proximity to human food and habitation.

Disease risks from vermin:

• Leptospirosis: Already NZ’s most common occupational zoonosis, transmitted through contact with urine from infected animals (primarily rats and livestock). Approximately 60-100 cases per year in NZ, predominantly among farmers and meat workers.⁶⁵ Under crisis conditions, increased rat populations near human habitation and more outdoor manual work increase exposure.
• Rat-bite fever: Uncommon but can occur with increased rat-human contact.
• Salmonellosis and other enteric infections: Rodent contamination of food stores.
• Plague: Yersinia pestis is not present in NZ’s rodent population and is extremely unlikely to be introduced under isolation. This is not a realistic concern.
• Flies and food contamination: Fly-borne transmission of enteric pathogens increases when waste management degrades.

8.2 Management approach

Chemical control: NZ holds stocks of rodenticides (brodifacoum, bromadiolone, and other anticoagulant rodenticides are widely used in NZ’s predator control programmes — DOC’s Predator Free 2050 initiative maintains substantial stocks).⁶⁶ These stocks should be rationed between conservation use and public health use. The primary public health allocation should be to food storage facilities, hospitals, and community kitchens.

Physical control: Traps (snap traps, kill traps) are already manufactured in NZ for the predator control programme. Goodnature traps (an NZ company) produces self-resetting traps.⁶⁷ These are a sustainable, non-chemical rodent control method. Production should continue and expand.

Environmental management: The most effective long-term rodent control is environmental: remove food sources, seal buildings, manage waste. Public health guidance should emphasise: - Store food in sealed, rodent-proof containers (metal, thick plastic, glass) - Manage waste — compost food waste in rodent-proof systems, do not leave waste exposed - Seal buildings — block rodent entry points in food storage areas - Community rubbish collection must continue. If municipal waste collection degrades, the public health consequences (rodents, flies, disease) are rapid.

Insect management: Fly screens on food preparation and eating areas. Proper waste management. Insecticides (pyrethroid-based household sprays) have limited stocks but long shelf life. NZ produces no insecticides domestically. Pyrethrum (from Tanacetum cinerariifolium) can be grown in NZ and processed into a natural insecticide, but the dependency chain requires: seed stock or established plants (verify availability from NZ nurseries or botanical gardens), 1–2 years for plants to reach harvestable maturity, harvesting and drying of flower heads at the correct stage (when pyrethrin content peaks), and solvent extraction (petroleum ether or ethanol) to produce usable pyrethrin concentrate. NZ would need either petroleum-derived solvents (finite imported stocks) or ethanol distillation capability (Doc #102). Feasibility: [B] — achievable but not trivial. This is a Phase 3–4 project.⁶⁸

---

9. BORDER HEALTH AND QUARANTINE [Phase 1–5]

9.1 The strategic imperative

NZ’s island status is only an advantage if the borders are managed. Post-event, maritime arrivals will include:

• Refugees from Pacific Island nations, Australia, or further afield (Doc #150)
• Trade crews from developing trans-Tasman or Pacific trade routes (Doc #138, #143)
• Returning NZ citizens who were abroad at the time of the event

These arrivals may carry diseases that NZ has eliminated or controlled:

• Cholera — risk from arrivals from countries with endemic cholera or where sanitation has collapsed post-event
• Typhoid and paratyphoid — same risk profile as cholera
• Malaria — arrivals from the Pacific (Papua New Guinea, Solomon Islands, Vanuatu have endemic malaria), though NZ lacks the Anopheles mosquito vector, so sustained transmission is extremely unlikely⁶⁹
• Drug-resistant tuberculosis — MDR-TB and XDR-TB are prevalent in some countries. A single untreated MDR-TB case in NZ would be extremely difficult to manage with limited drug stocks
• Measles and other vaccine-preventable diseases — if arriving populations have lower vaccination coverage than NZ’s
• Novel pathogens — the COVID-19 pandemic demonstrated that novel respiratory pathogens can emerge unpredictably. NZ’s isolation may protect it from novel pathogens circulating globally, but only if border health measures are maintained

9.2 Quarantine framework

Legal authority: The Health Act 1956 provides broad powers for quarantine of arriving vessels and persons. The Biosecurity Act 1993 provides additional authority for managing biological risks at the border. These legal frameworks are already established and familiar to port health officials.⁷⁰

Practical requirements:

1. Health screening at every port receiving vessels. A trained health officer (or trained designee — can be a nurse, community health worker, or trained customs official) screens all arriving persons for:

   • Fever (thermometry — thermometers are simple and reusable)
   • Respiratory symptoms (cough, difficulty breathing)
   • Diarrhoeal illness
   • Skin rashes (measles, chickenpox, other exanthems)
   • Visible signs of malnutrition or untreated illness
   • History of illness during the voyage

2. Quarantine facility at each major port. A designated building or area where arriving persons can be quarantined for observation. Duration: 14-21 days covers the incubation period of most acute infectious diseases (measles incubation 7-21 days, cholera 1-5 days, typhoid 6-30 days). The facility need not be purpose-built — a clean, ventilated building with basic sanitation, separated from the local population, is adequate.

3. Vessel inspection. Inspect arriving vessels for vermin (rats — which carry plague, leptospirosis, and other diseases), for sanitation conditions, and for food and water safety. Vessels with suspected disease on board may be held at anchor for quarantine before passengers disembark.

4. Vaccination of arrivals with any remaining vaccine stocks (particularly MMR and tetanus) if their vaccination status is unknown.

5. TB screening for all arrivals using chest X-ray (while equipment is functional) and symptom screening. This is particularly important for arrivals from high-TB-burden countries.

9.3 Balancing humanitarianism and public health

Quarantine of arriving refugees raises ethical tensions. People arriving by sea after weeks of dangerous travel are often malnourished, traumatised, and in need of immediate care. Detaining them in quarantine for 14-21 days may seem inhumane.

The public health argument is straightforward: a single case of cholera, MDR-TB, or measles introduced into NZ’s population — with its constrained pharmaceutical resources and eventually waning vaccine-derived immunity — could cause far more suffering than a quarantine period causes. Quarantine is not punishment; it is protection for both the arriving population and the receiving community.

The ethical resolution: quarantine should be humane — adequate food, shelter, sanitation, medical care, and human contact. It should be explained honestly to arrivals: “We are protecting you and our community. This is temporary.” Cultural sensitivity, translation services (where possible), and respect for dignity must be maintained. Doc #151 (Trans-Tasman Relations and Trade) and Doc #146 (Border Management) address the broader policy framework.

---

10. SURVEILLANCE SYSTEM ADAPTATION [Phase 1–5+]

10.1 The digital-to-paper transition

Under the baseline scenario, NZ’s digital infrastructure continues functioning for years (grid operational, domestic telecom intact). EpiSurv and electronic disease reporting continue. However, planning for digital degradation is prudent:

Phase 1-2 (digital systems functional): Operate as normal. Use the time to design and print paper-based fallback forms. Train staff in paper-based reporting.

Phase 3-4 (digital systems degrading): Some regional systems may fail — servers, networking equipment, workstations. Paper-based reporting at the local level, with data aggregated manually at district level and transmitted to national level via telephone, radio, or physical courier.

Phase 5+ (digital systems largely failed): Full paper-based surveillance. NZ itself used paper-based disease notification until EpiSurv was introduced in 1997, and many low- and middle-income countries continue to use paper-based systems today. It is slower and less complete than electronic surveillance but entirely functional for outbreak detection and disease monitoring.

10.2 Paper-based surveillance design

The paper form must be: - Simple: One page, minimal data fields — patient demographics (age, sex, location), disease suspected, date of onset, date of notification, outcome (alive/dead). Additional detail for outbreak investigation can be captured on separate forms. - Standardised nationally: Every district uses the same form so that data can be compared. - Pre-printed in bulk: Print runs of 100,000+ forms during Phase 1 while printing infrastructure is fully functional (Doc #5, Doc #29). - Supplied with clear instructions: A one-page guide for the notifying practitioner, explaining what to report, when, and how.

Aggregation and analysis: - District-level public health staff collect forms weekly from health facilities in their area - District epidemiologists (or trained public health nurses) tally cases by disease, age group, and location - Weekly summary reports transmitted to national level by whatever communication means is available (phone, radio, courier) - National-level analysis by ESR or Ministry of Health epidemiologists, producing weekly national surveillance bulletins that are distributed back to districts

This is how disease surveillance worked in NZ before computerisation. The performance gap compared with electronic surveillance is real: reporting delays increase from hours to days or weeks, completeness drops (historically, paper-based systems captured roughly 40–70% of cases compared with laboratory-linked electronic systems), and trend detection is slower. But paper-based surveillance is sufficient for detecting outbreaks and monitoring disease trends at the population level — it sustained effective public health for decades before computerisation.

10.3 Community-level surveillance

The community health worker (CHW) programme described in Recommended Action #10 extends surveillance beyond formal health facilities. CHWs are trained to:

• Recognise reportable conditions: Fever with rash (measles), prolonged cough (TB, pertussis), acute diarrhoea clusters (waterborne outbreak), jaundice (hepatitis)
• Report to the nearest health facility or public health office using the standardised form or a simplified community-level reporting card
• Conduct household visits to check on vulnerable individuals (elderly, disabled, chronically ill) and identify unreported illness

This approach is modelled on community health worker programmes that have been effective in low-resource settings across the Pacific, Southeast Asia, and sub-Saharan Africa.⁷¹ NZ has relevant domestic precedents: the Whanau Ora navigator programme, Plunket nurses (who have conducted home visits to NZ families since 1907), and Hauora Maori community health workers already provide community-level health outreach. Marae are existing community facilities with kitchens, sleeping accommodation, and gathering spaces, and serve as natural sites for CHW deployment, health education, and outbreak response — the whanau ora model, which integrates health with community and family support, aligns well with the community-based public health approach described here.⁷² NZ’s advantage is that it starts with a functional health system, a literate population, and existing community health worker models that can be expanded — CHW training can be faster and more effective than in settings where baseline health literacy is low.

10.4 Laboratory capacity preservation

NZ’s public health laboratory network — ESR’s national reference laboratories, hospital diagnostic laboratories, and community laboratory services — depends on imported reagents and consumables. As these deplete, laboratory capability degrades.

Priority preservation:

1. Microscopy: The oldest and most sustainable diagnostic technique. Requires a microscope (durable, repairable — NZ hospitals, universities, and school laboratories hold hundreds of brightfield microscopes), glass slides (producible with basic glasswork capability or drawn from existing stocks), and staining reagents. Domestic stain production requires: crystal violet (a synthetic dye — existing laboratory and industrial stocks will last years; long-term domestic synthesis requires intermediate organic chemistry capability), Gram’s iodine (iodine from seaweed extraction or existing stocks, plus potassium iodide), and for TB diagnosis, Ziehl-Neelsen stain (carbolfuchsin from phenol and basic fuchsin dye, acid-alcohol from ethanol and hydrochloric acid, and methylene blue). Phenol can be derived from coal tar distillation (Doc #119); ethanol from fermentation; HCl from salt and sulfuric acid (Doc #116). The dyes themselves (fuchsin, methylene blue) are the hardest link — existing stocks must be rationed, and domestic synthesis requires advanced organic chemistry that is unlikely before Phase 5–6.⁷³ Microscopy can diagnose TB (acid-fast bacilli), malaria (blood film), many bacterial infections (Gram stain), and parasites (stool microscopy).

2. Culture and sensitivity (basic): Blood agar and other culture media can be produced from locally available materials, but the dependency chain requires: harvesting agarophyte seaweed (Pterocladia lucida from rocky intertidal shores throughout NZ, or Gracilaria chilensis farmed commercially in the Kaipara Harbour and other northern estuaries), boiling and filtering to extract agar (requires clean water, heat source, and filtration equipment), sterile collection of sheep blood (requires sterile syringes and anticoagulant — sodium citrate, which is producible from citric acid and sodium hydroxide), combining agar and blood under sterile conditions, and pouring into sterile Petri dishes (glass dishes are reusable; production requires glassblowing capability or existing stocks).⁷⁴ The resulting culture media is adequate for growing most common bacterial pathogens and performing basic antibiotic susceptibility testing, though quality is lower than commercial media — expect higher contamination rates and some organisms that grow poorly on non-standardised media. This capability should be maintained at regional hospital laboratories.

3. Serology (simple): RPR testing for syphilis, basic blood typing, and simple agglutination tests may be maintainable using locally produced reagents. Complex serology (ELISA, immunofluorescence) will fail as imported kits deplete.

4. PCR and molecular diagnostics: These are the first capabilities to be lost — PCR requires polymerase enzymes, primers, nucleotides, and equipment (thermal cyclers) that are entirely imported and cannot be produced domestically in the foreseeable future. Ration remaining PCR reagents for the highest-value uses (outbreak confirmation, novel pathogen identification) and plan clinical workflows around their absence.

---

CRITICAL UNCERTAINTIES

Uncertainty	Impact if wrong	Resolution method
Severity and duration of nuclear winter	Determines severity of nutritional deficiency, housing cold stress, and respiratory disease burden	Monitor actual conditions; adjust public health response to observed impacts rather than modelled predictions
Water treatment transition success	If water treatment fails in a major urban centre, waterborne disease outbreak is the most immediate mass-casualty public health risk	Doc #48 implementation is the highest-priority public health dependency. Public health staff must be embedded in water treatment planning
Vaccine stock levels and cold-chain integrity	Overestimated stocks mean earlier-than-planned loss of vaccination capability; cold chain failure could destroy stocks suddenly	Immediate inventory (Recommended Action #3). Backup power at all vaccine storage facilities
TB reactivation rate under crisis conditions	If higher than estimated, TB could become NZ’s dominant infectious disease within a decade, consuming a disproportionate share of antibiotic stocks	Active TB surveillance from Phase 1. Housing and nutrition interventions to reduce reactivation risk
Refugee and maritime arrival numbers	Determines scale of border health challenge — more arrivals mean more screening, more quarantine capacity, more disease introduction risk	Coordinate with border management (Doc #145) and prepare quarantine capacity in excess of initial estimates
Digital infrastructure longevity	Determines how long electronic surveillance functions and when paper fallback is needed	Design and print paper systems during Phase 1 regardless of digital system status
Antibiotic resistance patterns	If resistant organisms emerge or are imported, treatment options narrow faster than drug supply alone would suggest	Maintain antimicrobial stewardship; preserve laboratory culture and sensitivity testing as long as possible
Population compliance with quarantine and hygiene measures	If public trust in government erodes (Doc #2, Doc #144), compliance with quarantine, hygiene guidance, and surveillance cooperation declines	Transparent communication, fair and humane quarantine, visible equity in public health measures
Rodent population dynamics	If waste management fails in urban areas, rodent populations could increase dramatically, accelerating leptospirosis and food contamination	Maintain waste collection as essential service; distribute vermin control guidance and supplies
Laboratory reagent depletion rates	Determines when surveillance shifts from laboratory-confirmed to clinical case definitions — affects diagnostic accuracy	Inventory all laboratory consumables; ration reagents for highest-value uses; build local microscopy and culture capability

---

CROSS-REFERENCES

Document	Relationship
Doc #1 — National Emergency Stockpile Strategy	Vaccine stocks, laboratory reagents, and pest control chemicals are stockpile items requiring requisition and rationing
Doc #2 — Public Communication	Public health messaging — hygiene guidance, quarantine communication, disease outbreak communication — must be coordinated with the national communication strategy
Doc #3 — Food Rationing and Distribution	Nutritional adequacy of rations directly determines nutritional deficiency disease risk. Ration composition is a public health intervention
Doc #156 — Skills Census	Inventory of public health workforce, laboratory capacity, and vaccine stocks feeds into both the census and the public health plan
Doc #48 — Water Treatment Without Imports	Water safety is the single most important public health dependency. Failure of water treatment is the most immediate mass-casualty public health risk
Doc #49 — Wastewater Management	Wastewater management failure leads directly to waterborne and faecal-oral disease increase
Doc #116 — Pharmaceutical Rationing	Antibiotic availability determines treatment capacity for infectious diseases. Vaccine stocks managed under the pharmaceutical triage framework
Doc #119 — Local Pharmaceutical Production	Domestic production of antibiotics, and eventually vaccines, is the long-term solution for public health consumable needs
Doc #122 — Mental Health	Mental health is a public health issue. Population-level psychological deterioration affects substance use, domestic violence, suicide, and workforce capacity
Doc #123 — Midwifery and Maternity Care	Antenatal screening (syphilis, hepatitis B, GBS), neonatal health, and maternal nutrition are public health concerns managed through the maternity system
Doc #138 — Sailing Vessel Design	Maritime trade vessels are the primary pathway for disease importation. Vessel crews need health screening
Doc #146 — Border Management	Border health screening and quarantine capability is a subset of border management. Public health requirements must be integrated into port operations
Doc #151 — Trans-Tasman Relations and Trade	Refugee and trade arrivals from Australia and the Pacific present the primary disease importation risk. Health screening protocols must be agreed as part of bilateral arrangements
Doc #163 — Housing Insulation	Housing quality directly determines respiratory disease burden. Insulation and heating are public health interventions

---

---

1. Institute of Environmental Science and Research (ESR). “Notifiable Diseases in New Zealand: Annual Report.” Published annually. https://www.esr.cri.nz/our-expertise/public-health/survei... — NZ’s notifiable disease data shows low incidence of most vaccine-preventable diseases, moderate rates of enteric disease (campylobacteriosis is the most common), low TB incidence, and no endemic malaria, cholera, or typhoid. NZ has eliminated polio (last case 1962), and measles transmission has been repeatedly interrupted (though outbreaks from imported cases recur).↩︎

2. Cambie RC, Ferguson LR. “Potential functional foods in the traditional Maori diet.” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 523-524 (2003): 109-117. Also: Williams PM. “Te Rongoa Maori: Maori Medicine.” Penguin Books NZ, 1996. Traditional Maori food sources including puha, watercress, pikopiko, and kaimoana provide diverse micronutrients including vitamin C, iron, and omega-3 fatty acids.↩︎

3. Government Inquiry into Havelock North Drinking Water. “Report of the Havelock North Drinking Water Inquiry: Stage 1.” May 2017. https://www.dia.govt.nz/Government-Inquiry-into-Havelock-... — Approximately 5,500 people became ill (estimated from serological and epidemiological data), at least 45 were hospitalised, and 3-4 deaths were attributed to the campylobacteriosis outbreak caused by contamination of a bore water supply.↩︎

4. Jaine R, Baker M, Venugopal K. “Acute rheumatic fever associated with household crowding in a developed country.” Pediatric Infectious Disease Journal 30.4 (2011): 315-319. Also: Ministry of Health. “Rheumatic Fever” — NZ’s rheumatic fever rates are among the highest in the developed world, with Maori and Pacific children disproportionately affected. Household overcrowding is the strongest modifiable risk factor.↩︎

5. ESR. “Tuberculosis in New Zealand: Annual Report.” Published annually. https://www.esr.cri.nz/ — NZ’s TB incidence is approximately 6-7 per 100,000, with approximately 300-350 notified cases per year. Most cases occur in foreign-born individuals from high-incidence countries. The distribution is geographically uneven, with Auckland having the highest case rates.↩︎

6. Ministry of Health. “National and DHB Immunisation Data.” https://www.health.govt.nz/our-work/preventative-health-w... — NZ’s immunisation coverage for the primary childhood series is approximately 92-95% at age 2, varying by DHB/region and vaccine. MMR coverage has been approximately 92-94% in recent years. Coverage is lower in some Maori and Pacific communities.↩︎

7. Health Act 1956 (NZ), Part 3A — Infectious and notifiable diseases. Medical Officers of Health have statutory powers to require medical examination, quarantine, isolation, and closure of premises. These powers were used during COVID-19 and remain in force. Also: COVID-19 Public Health Response Act 2020 (NZ), which provided additional enforcement mechanisms.↩︎

8. Biosecurity Act 1993 (NZ), Part 4 — Border management. Health Act 1956, Sections 96-97 — Quarantine of ships and persons. NZ has established legal frameworks for quarantine of arriving vessels and persons, exercised regularly through the managed isolation and quarantine (MIQ) system during COVID-19.↩︎

9. Perry HB, Zulliger R, Rogers MM. “Community health workers in low-, middle-, and high-income countries: an overview of their history, recent evolution, and current effectiveness.” Annual Review of Public Health 35 (2014): 399-421. Community health worker programmes have demonstrated effectiveness across diverse settings for disease surveillance, health education, and basic clinical care.↩︎

10. Estimate based on the Havelock North outbreak (approximately 5,500 ill from a population served of approximately 14,000 — roughly 40% attack rate) scaled to a portion of Auckland’s water supply. The range 100,000–400,000 reflects uncertainty about which water supply systems could be affected, the pathogen involved, and the speed of detection and response. The Havelock North Inquiry (2017) provides the NZ-specific evidence base.↩︎

11. WHO. “Measles Fact Sheet.” https://www.who.int/news-room/fact-sheets/detail/measles — Measles case fatality rate in well-nourished populations with access to care is approximately 1-3 per 1,000 cases. In malnourished populations with poor access to care, case fatality can exceed 5-10 per 1,000 and in some settings has been reported at 10-30 per 1,000.↩︎

12. WHO. “Global Tuberculosis Report.” Published annually. https://www.who.int/teams/global-tuberculosis-programme/t... — TB case fatality rate without treatment is approximately 50% over 1-2 years (historical data from pre-chemotherapy era). With standard treatment, cure rates exceed 85%. Multi-drug resistant TB has substantially lower cure rates and requires longer, more toxic treatment regimens.↩︎

13. Ministry of Health workforce data and Health Workforce New Zealand reports. NZ’s public health workforce includes Medical Officers of Health (approximately 15-20 nationally), public health physicians, epidemiologists, public health nurses, health protection officers, and environmental health officers. Total public health workforce is approximately 2,000-3,000 depending on definition and counting methodology.↩︎

14. Ministry of Health / Manatu Hauora. “Communicable Disease Control Manual.” https://www.health.govt.nz/publication/communicable-disea... — The official reference for NZ’s communicable disease surveillance and control framework. Describes institutional roles, notification processes, and disease-specific control measures.↩︎

15. Institute of Environmental Science and Research (ESR). https://www.esr.cri.nz/ — ESR operates EpiSurv (national notifiable disease database), provides reference laboratory services for infectious diseases, environmental health, and food safety. ESR’s public health function is funded by the Ministry of Health and constitutes a core component of NZ’s disease surveillance infrastructure.↩︎

16. Health Act 1956 (NZ), Part 3A — Infectious and notifiable diseases. Medical Officers of Health have statutory powers to require medical examination, quarantine, isolation, and closure of premises. These powers were used during COVID-19 and remain in force. Also: COVID-19 Public Health Response Act 2020 (NZ), which provided additional enforcement mechanisms.↩︎

17. Health Act 1956, Schedule 2 — Notifiable infectious diseases. The schedule lists approximately 50 conditions that must be reported by medical practitioners and laboratories to the Medical Officer of Health. The list is updated periodically by the Minister of Health.↩︎

18. Institute of Environmental Science and Research (ESR). “Notifiable Diseases in New Zealand: Annual Report.” Published annually. https://www.esr.cri.nz/our-expertise/public-health/survei... — NZ’s notifiable disease data shows low incidence of most vaccine-preventable diseases, moderate rates of enteric disease (campylobacteriosis is the most common), low TB incidence, and no endemic malaria, cholera, or typhoid. NZ has eliminated polio (last case 1962), and measles transmission has been repeatedly interrupted (though outbreaks from imported cases recur).↩︎

19. ESR. “Notifiable Diseases in New Zealand: Annual Report” — annual disease-specific case counts, rates, and trends. The figures in the table are approximate, based on recent years’ data (which fluctuates annually). Campylobacteriosis figures have declined from peaks of approximately 15,000+ cases/year in the early 2000s following poultry industry interventions.↩︎

20. Jefferies S, French N, Gilkison C, et al. “COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study.” Lancet Public Health 5.11 (2020): e612-e623. NZ’s border-based elimination strategy prevented community transmission for extended periods during 2020-2021.↩︎

21. Cutler D, Miller G. “The Role of Public Health Improvements in Health Advances: The Twentieth-Century United States.” Demography 42.1 (2005): 1-22. Also: McKeown T. “The Role of Medicine: Dream, Mirage, or Nemesis?” Nuffield Provincial Hospitals Trust, 1976. The historical evidence strongly supports clean water and sanitation as the primary drivers of infectious disease decline in developed countries, predating antibiotics and most vaccines.↩︎

22. ESR. “Notifiable Diseases in New Zealand: Annual Report” — annual disease-specific case counts, rates, and trends. The figures in the table are approximate, based on recent years’ data (which fluctuates annually). Campylobacteriosis figures have declined from peaks of approximately 15,000+ cases/year in the early 2000s following poultry industry interventions.↩︎

23. Betancourt WQ, Rose JB. “Drinking water treatment processes for removal of Cryptosporidium and Giardia.” Veterinary Parasitology 126.1-2 (2004): 219-234. Cryptosporidium oocysts are resistant to standard chlorination at concentrations used for drinking water treatment. Effective removal requires filtration (slow sand filtration is effective) or UV treatment.↩︎

24. Sobsey MD, Pfaender FK. “Evaluation of the H₂S Method for Detection of Fecal Contamination of Drinking Water.” World Health Organization, 2002. H₂S paper strip tests detect hydrogen sulfide-producing bacteria associated with faecal contamination. They are field-deployable, require no laboratory infrastructure, and can be produced locally.↩︎

25. Ministry of Health / Manatu Hauora. “Drinking-Water Standards for New Zealand” and associated compliance data. Approximately 15-20% of NZ’s population relies on private water supplies not subject to routine compliance monitoring.↩︎

26. Riley M. “Maori Healing and Herbal: New Zealand Ethnobotanical Sourcebook.” Viking Sevenseas NZ Ltd, 1994. Also: Brooker SG, Cambie RC, Cooper RC. “New Zealand Medicinal Plants.” Heinemann, 1981. Kawakawa, manuka, and koromiko have documented traditional uses that align with modern understanding of their pharmacological properties.↩︎

27. Best E. “The Maori.” Memoirs of the Polynesian Society, Vol. 5, 1924. Also: Buck PH (Te Rangi Hiroa). “The Coming of the Maori.” Whitcombe and Tombs, 1949. Traditional Maori tapu systems regulated activities related to water, food preparation, and bodily functions, serving practical hygiene functions alongside spiritual significance.↩︎

28. Ministry of Health. “Eating and Activity Guidelines for New Zealand Adults” and the NZ Adult Nutrition Survey (2008/09). Pre-event nutritional status in NZ is generally adequate, though significant disparities exist by income, ethnicity, and region. Iron deficiency is the most common nutritional deficiency.↩︎

29. Carpenter KJ. “The History of Scurvy and Vitamin C.” Cambridge University Press, 1986. Scurvy develops after approximately 1-3 months of dietary vitamin C depletion (<10 mg/day). As little as 10 mg/day prevents scurvy (compared with the recommended daily intake of 75-90 mg for adults). A single medium-sized potato contains approximately 20 mg of vitamin C.↩︎

30. The New Zealand Blackcurrant Co-operative and Plant & Food Research. Blackcurrants (Ribes nigrum) contain approximately 180 mg vitamin C per 100 g — among the highest of any temperate fruit. NZ is a significant global blackcurrant producer, with most production in Canterbury. The plants are cold-hardy and may tolerate nuclear winter conditions better than many other fruit crops.↩︎

31. Hegyi J, Schwartz RA, Hegyi V. “Pellagra: dermatitis, dementia, and diarrhea.” International Journal of Dermatology 43.1 (2004): 1-5. Pellagra results from deficiency of niacin (vitamin B3) or its precursor tryptophan. The risk is primarily in populations with maize-dominant diets without nixtamalization. NZ’s meat-and-dairy-based diet provides adequate niacin.↩︎

32. Lonsdale D. “A Review of the Biochemistry, Metabolism and Clinical Benefits of Thiamin(e) and Its Derivatives.” Evidence-Based Complementary and Alternative Medicine 3.1 (2006): 49-59. Beriberi results from thiamine (vitamin B1) deficiency, primarily in populations dependent on polished white rice. Whole grains, meat, and legumes provide adequate thiamine.↩︎

33. Ministry of Health. “NZ Food NZ Children: Key results of the 2002 National Children’s Nutrition Survey.” Also: University of Otago and Ministry of Health. “A Focus on Nutrition: Key findings of the 2008/09 New Zealand Adult Nutrition Survey.” Iron deficiency is the most common nutritional deficiency in NZ, affecting approximately 2-5% of women of reproductive age and higher rates in Maori and Pacific populations.↩︎

34. Rockell JE, Skeaff CM, Williams SM, Green TJ. “Serum 25-hydroxyvitamin D concentrations of New Zealanders aged 15 years and older.” Osteoporosis International 17.9 (2006): 1382-1389. A significant proportion of NZers have vitamin D levels below recommended thresholds, particularly in winter, at southern latitudes, and in darker-skinned populations.↩︎

35. WHO. “Vitamin A deficiency.” Global Health Observatory data. Vitamin A deficiency is not currently a public health problem in NZ due to adequate dairy and vegetable intake. NZ dairy products (butter, cheese, whole milk) are good sources of preformed vitamin A.↩︎

36. Cambie RC, Ferguson LR. “Potential functional foods in the traditional Maori diet.” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 523-524 (2003): 109-117. Also: Williams PM. “Te Rongoa Maori: Maori Medicine.” Penguin Books NZ, 1996. Traditional Maori food sources including puha, watercress, pikopiko, and kaimoana provide diverse micronutrients including vitamin C, iron, and omega-3 fatty acids.↩︎

37. Riley M. “Maori Healing and Herbal: New Zealand Ethnobotanical Sourcebook.” Viking Sevenseas NZ Ltd, 1994. Also: Brooker SG, Cambie RC, Cooper RC. “New Zealand Medicinal Plants.” Heinemann, 1981. Kawakawa, manuka, and koromiko have documented traditional uses that align with modern understanding of their pharmacological properties.↩︎

38. PHARMAC and Medsafe data. NZ has no domestic vaccine manufacturing facility. All vaccines administered in NZ are imported from international manufacturers (primarily GSK, Pfizer, Sanofi Pasteur, Seqirus, MSD). This complete import dependence is the fundamental vulnerability for NZ’s immunisation programme under isolation.↩︎

39. NZ’s annual birth cohort is approximately 58,000–62,000 (Stats NZ, Births and Deaths data). The National Immunisation Schedule delivers multiple doses per child across the first 12 months, plus booster doses, adolescent vaccines, pregnancy vaccines, and annual influenza vaccination for eligible adults. The aggregate dose count is not publicly reported at national level; the 1.5–2.5 million range is an estimate based on schedule doses per birth cohort plus adult programmes. Actual figures would be available from PHARMAC procurement data.↩︎

40. Ministry of Health. “National Immunisation Schedule.” https://www.health.govt.nz/your-health/healthy-living/imm... — The schedule is updated periodically. The vaccines listed are the core programme as of early 2026. Additional funded vaccines (e.g., for high-risk groups) are not listed exhaustively.↩︎

41. Vaccine stock levels are commercially sensitive and not publicly reported at aggregate national level. The 3-12 month estimate is based on general pharmaceutical supply chain practices and the seasonal nature of some vaccine procurement (e.g., influenza). Actual stock levels would be determined through the immediate inventory process (Recommended Action #3).↩︎

42. Cold chain for vaccines in NZ is managed through the National Immunisation Programme, with distributed storage at regional and district levels. The same cold-chain infrastructure that protects vaccine stocks also protects insulin and other cold-chain pharmaceuticals (Doc #116). Backup power at cold-chain storage facilities protects multiple high-value pharmaceutical categories simultaneously.↩︎

43. WHO. “Measles Fact Sheet.” https://www.who.int/news-room/fact-sheets/detail/measles — Measles case fatality rate in well-nourished populations with access to care is approximately 1-3 per 1,000 cases. In malnourished populations with poor access to care, case fatality can exceed 5-10 per 1,000 and in some settings has been reported at 10-30 per 1,000.↩︎

44. WHO. “Tetanus” fact sheet. https://www.who.int/news-room/fact-sheets/detail/tetanus — Tetanus case fatality rate is approximately 10-70% depending on age and access to intensive care (mechanical ventilation, sedation, wound care). Without intensive care, case fatality approaches 50% or higher. Neonatal tetanus has an even higher fatality rate.↩︎

45. WHO. “Pertussis” fact sheet. https://www.who.int/news-room/fact-sheets/detail/pertussis — Pertussis (whooping cough) is most dangerous in infants under 6 months, with a case fatality rate of approximately 1-2% in this age group. Older children and adults have much lower mortality but contribute to transmission.↩︎

46. Stats NZ. “Births and Deaths.” https://www.stats.govt.nz/ — NZ’s recent annual live births have ranged from approximately 55,000 to 62,000. Under crisis conditions, birth rates may decline further due to contraceptive use, delayed childbearing, reduced fertility from malnutrition, and increased pregnancy loss.↩︎

47. ESR. “Measles in New Zealand, 2019.” The 2019 NZ measles outbreak (approximately 2,194 confirmed cases) was the largest in decades, concentrated in under-vaccinated populations (particularly in the Samoan community in South Auckland and in Christchurch). The outbreak demonstrated the vulnerability of gaps in vaccine coverage.↩︎

48. WHO. “Vitamin A supplements for children with measles.” Cochrane evidence summary. Vitamin A supplementation reduces measles mortality by approximately 50% in children with vitamin A deficiency and reduces the risk of serious complications in all children with measles. The WHO recommends vitamin A for all children with measles.↩︎

49. WHO. “Global Tuberculosis Report.” Published annually. https://www.who.int/teams/global-tuberculosis-programme/t... — TB case fatality rate without treatment is approximately 50% over 1-2 years (historical data from pre-chemotherapy era). With standard treatment, cure rates exceed 85%. Multi-drug resistant TB has substantially lower cure rates and requires longer, more toxic treatment regimens.↩︎

50. NZ AIDS Foundation / Burnett Foundation Aotearoa. https://www.burnettfoundation.org.nz/ — Approximately 1,200-1,500 people living with diagnosed HIV in NZ (data approximate and changing). Total including undiagnosed estimated at perhaps 2,000-3,000. NZ’s HIV prevalence is low by international standards.↩︎

51. WHO. “Global Tuberculosis Report.” The commonly cited figure of 10–15 secondary infections per untreated active TB case per year derives from the pre-chemotherapy natural history literature. More recent modelling (e.g., Vynnycky E, Fine PE. “The natural history of tuberculosis.” Epidemiology and Infection 119.2 (1997): 183-201) suggests a range of approximately 5–15 depending on living conditions, ventilation, and duration of infectiousness. In well-ventilated, uncrowded settings the number is lower; in overcrowded housing it is higher.↩︎

52. ESR. “Tuberculosis in New Zealand: Annual Report.” Published annually. https://www.esr.cri.nz/ — NZ’s TB incidence is approximately 6-7 per 100,000, with approximately 300-350 notified cases per year. Most cases occur in foreign-born individuals from high-incidence countries. The distribution is geographically uneven, with Auckland having the highest case rates.↩︎

53. Estimated. NZ does not have comprehensive data on latent TB infection prevalence. The estimate is based on the proportion of NZ’s population born in high-TB-incidence countries (approximately 25-30% of the population is overseas-born, with significant proportions from countries with TB incidence >50 per 100,000) and approximate latent infection rates in those populations. The true number is highly uncertain.↩︎

54. Isoniazid (isonicotinic acid hydrazide) is a relatively simple organic molecule first synthesised in 1912. Its synthesis from isonicotinic acid (derived from pyridine via oxidation) and hydrazine is well-documented in the chemical literature. Domestic production is feasible with intermediate-level organic chemistry capability — Feasibility [B-C] per Doc #119 framework.↩︎

55. WHO. “Treatment of Tuberculosis: Guidelines.” 4th edition, 2010. Directly Observed Therapy (DOT) — where a health worker or trained community member watches the patient swallow each dose — improves treatment completion rates and reduces drug resistance development. DOT is the standard of care for TB treatment globally.↩︎

56. Colditz GA, Berkey CS, Mosteller F, et al. “The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.” Pediatrics 96.1 (1995): 29-35. BCG is approximately 70-80% effective against severe forms of childhood TB (TB meningitis, miliary TB) but has variable and generally lower efficacy against adult pulmonary TB.↩︎

57. Howden-Chapman P, Matheson A, Crane J, et al. “Effect of insulating existing houses on health inequality: cluster randomised study in the community.” BMJ 334.7591 (2007): 460. The Housing, Insulation and Health study demonstrated that insulating NZ homes reduced respiratory illness, improved self-rated health, and reduced GP visits. Also: WHO. “Housing and Health Guidelines.” 2018. Recommends minimum indoor temperatures of 18 degrees C.↩︎

58. Jaine R, Baker M, Venugopal K. “Acute rheumatic fever associated with household crowding in a developed country.” Pediatric Infectious Disease Journal 30.4 (2011): 315-319. Also: Ministry of Health. “Rheumatic Fever” — NZ’s rheumatic fever rates are among the highest in the developed world, with Maori and Pacific children disproportionately affected. Household overcrowding is the strongest modifiable risk factor.↩︎

59. Nuclear winter temperature modelling for NZ is subject to significant uncertainty. Robock A, Oman L, Stenchikov GL. “Nuclear winter revisited with a modern climate model and current nuclear arsenals.” Journal of Geophysical Research 112 (2007): D13107. NZ’s maritime climate buffers temperature extremes; modelled cooling for the Southern Hemisphere mid-latitudes ranges from approximately 2–8 degrees C depending on the conflict scenario and model used. The lower end assumes a regional exchange; the upper end assumes a full-scale strategic exchange.↩︎

60. Heart Foundation of NZ and Ministry of Health. “Rheumatic Fever Prevention Programme.” School-based sore throat testing and treatment programmes, primarily in Northland, Auckland, Bay of Plenty, and other high-risk areas, have demonstrated effectiveness in reducing acute rheumatic fever incidence by approximately 40-60% in target populations.↩︎

61. WHO. “Guidelines for the Management of Sexually Transmitted Infections.” Syndromic management — treating STIs based on clinical presentation (urethral discharge syndrome, genital ulcer syndrome, vaginal discharge syndrome) rather than laboratory-confirmed diagnosis — is the WHO-recommended approach for settings with limited laboratory capacity. It is less specific than laboratory-based diagnosis but pragmatically effective.↩︎

62. Gallo MF, Grimes DA, Lopez LM, Schulz KF. “Nonlatex versus latex male condoms for contraception.” Cochrane Database of Systematic Reviews 2006, Issue 1. Animal-membrane (lambskin) condoms prevent pregnancy but have pores that may allow passage of viral particles (HIV, HPV, hepatitis B). They are less effective than latex condoms for STI prevention.↩︎

63. The rapid plasma reagin (RPR) test for syphilis uses a non-treponemal antigen (cardiolipin-lecithin-cholesterol) to detect reagin antibodies. The reagent components are chemically simpler than most immunological test kits and may be producible with intermediate chemistry capability. This requires verification by laboratory specialists but is plausible.↩︎

64. NZ AIDS Foundation / Burnett Foundation Aotearoa. https://www.burnettfoundation.org.nz/ — Approximately 1,200-1,500 people living with diagnosed HIV in NZ (data approximate and changing). Total including undiagnosed estimated at perhaps 2,000-3,000. NZ’s HIV prevalence is low by international standards.↩︎

65. ESR. “Notifiable Diseases in New Zealand: Annual Report” — leptospirosis section. NZ’s leptospirosis incidence is approximately 60-100 cases per year, predominantly among dairy farmers, meat workers, and other occupational groups with animal contact. The disease is transmitted through contact with urine from infected animals, primarily rats and livestock.↩︎

66. Department of Conservation (DOC). “Predator Free 2050” and associated publications. NZ’s large-scale predator control programme maintains substantial stocks of anticoagulant rodenticides (brodifacoum, bromadiolone) and supports NZ-manufactured kill traps (Goodnature, Trapinator, and other products). This infrastructure provides both rodenticide stocks and trap manufacturing capability relevant to public health rodent control.↩︎

67. Department of Conservation (DOC). “Predator Free 2050” and associated publications. NZ’s large-scale predator control programme maintains substantial stocks of anticoagulant rodenticides (brodifacoum, bromadiolone) and supports NZ-manufactured kill traps (Goodnature, Trapinator, and other products). This infrastructure provides both rodenticide stocks and trap manufacturing capability relevant to public health rodent control.↩︎

68. Pyrethrum is derived from the flowers of Tanacetum cinerariifolium (Dalmatian chrysanthemum). The plant grows well in temperate climates and has been cultivated commercially in NZ’s climate zone. Pyrethrin extraction from dried flower heads using solvents is a relatively simple process. The resulting insecticide is effective against a broad range of insects and has low mammalian toxicity.↩︎

69. NZ has no established Anopheles mosquito populations. The primary mosquito species in NZ (Culex quinquefasciatus, Aedes notoscriptus) do not transmit malaria. While Anopheles mosquitoes could theoretically be introduced, NZ’s cool climate is unfavourable for sustained malaria transmission. The risk of imported malaria cases in individual travellers exists, but sustained local transmission is extremely unlikely.↩︎

70. Biosecurity Act 1993 (NZ), Part 4 — Border management. Health Act 1956, Sections 96-97 — Quarantine of ships and persons. NZ has established legal frameworks for quarantine of arriving vessels and persons, exercised regularly through the managed isolation and quarantine (MIQ) system during COVID-19.↩︎

71. Perry HB, Zulliger R, Rogers MM. “Community health workers in low-, middle-, and high-income countries: an overview of their history, recent evolution, and current effectiveness.” Annual Review of Public Health 35 (2014): 399-421. Community health worker programmes have demonstrated effectiveness across diverse settings for disease surveillance, health education, and basic clinical care.↩︎

72. Durie M. “Whaiora: Maori Health Development.” Oxford University Press, 1994. Also: Mark GT, Lyons AC. “Maori healers’ views on wellbeing: the importance of mind, body, spirit, family and land.” Social Science & Medicine 70.11 (2010): 1756-1764. Maori health frameworks integrate physical, mental, spiritual, and community dimensions — an approach that aligns with the holistic public health model needed under recovery conditions.↩︎

73. Microscopy is the foundational diagnostic technique for most infectious diseases. It requires only a brightfield microscope (robust, long-lived instruments that can be maintained for decades), glass slides, coverslips, and staining reagents. The Ziehl-Neelsen stain for TB uses carbolfuchsin (phenol + basic fuchsin dye), acid-alcohol (ethanol + HCl), and methylene blue — all producible with basic chemistry capability. Gram stain uses crystal violet, Gram’s iodine, ethanol, and safranin — similarly producible.↩︎

74. Agar is derived from agarophyte seaweed species. NZ has native and naturalised agarophyte species including Pterocladia lucida and Gracilaria chilensis. Agar extraction from seaweed involves boiling in water, filtering, and gelling — a process that requires no imported reagents. Sheep blood for blood agar is abundantly available in NZ. Together, these allow NZ to produce basic bacteriological culture media domestically.↩︎